Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Authors' conclusion
In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.
Study context
- Population
- Adults with obesity/overweight and T2D (Study 1; mean BMI 35.4 kg/m²) or clinical obesity without T2D (Study 2; mean BMI 37.4 kg/m²)
- Comparison
- Retatrutide vs placebo
- Primary endpoint
- Placebo-adjusted change from baseline in lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Placebo-adjusted change from baseline with retatrutide (Study 1, Study 2)
- Non-HDL cholesterol, Study 1 (up to)
- −21.0%
- Non-HDL cholesterol, Study 2 (up to)
- −26.9%
- Apolipoprotein B, Study 1
- −21.4%
- Apolipoprotein B, Study 2
- −24.2%
- Total TG-rich lipoprotein particles, Study 1
- −22.5%
- Total TG-rich lipoprotein particles, Study 2
- −33.7%
- Large TG-rich lipoprotein particles, Study 1
- −84.4%
- Large TG-rich lipoprotein particles, Study 2
- −76.6%
- TG-rich lipoprotein cholesterol, Study 1
- −29.4%
- TG-rich lipoprotein cholesterol, Study 2
- −38.6%
- Total LDL particles, Study 1
- −19.7%
- Total LDL particles, Study 2
- −23.5%
- Small LDL particles, Study 1
- −32.6%
- Small LDL particles, Study 2
- −32.3%
- High-sensitivity C-reactive protein, Study 2 (not significant in Study 1)
- −54.8%
- Interleukin-6, Study 2 (not significant in Study 1)
- −29.6%
Original publication
Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →